Dr. Lallas on Understanding Immunotherapy in GU Malignancies

Costas Lallas, MD
Published: Tuesday, Sep 05, 2017



Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary (GU) malignancies.

The rise of multidisciplinary care in GU malignancies means that it is no longer solely the job of the oncologists to administer novel agents such as immunotherapy.

Lallas says that this rise in multidisciplinary care, in addition to workforce shortages, means that it is very important for urologists and advanced practice providers to understand chemotherapy and immunotherapy regimens for GU malignancies.



Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary (GU) malignancies.

The rise of multidisciplinary care in GU malignancies means that it is no longer solely the job of the oncologists to administer novel agents such as immunotherapy.

Lallas says that this rise in multidisciplinary care, in addition to workforce shortages, means that it is very important for urologists and advanced practice providers to understand chemotherapy and immunotherapy regimens for GU malignancies.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x